Evidence map›Paper›PMID 22308454›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2012

Genome-wide siRNA screen for mediators of NF-κB activation.

Benjamin E Gewurz, Fadi Towfic, Jessica C Mar, Nicholas P Shinners, Kaoru Takasaki, Bo Zhao, Ellen D Cahir-McFarland, John Quackenbush, Ramnik J Xavier, Elliott Kieff

Open access · bronzeAbstract readValidation Study
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.

0numbers the graph read from it
0cells of the map it votes in
78citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

78 citing papers in PubMed, 113 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. The Characterization and Differential Analysis of mAnimals : an open access journal from MDPI · 2023
    Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

18 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Benjamin E GewurzDepartment of Medicine and Microbiology and Molecular Genetics, Channing Laboratory, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Fadi Towfic
Jessica C Mar
Nicholas P Shinners
Kaoru Takasaki
Bo Zhao
Ellen D Cahir-McFarland
John Quackenbush
Ramnik J Xavier
Elliott Kieff
Brigham and Women's Hospital · USHarvard University · USBroad Institute · USDana-Farber Cancer Institute · USMassachusetts General Hospital · US

Funding

Treatments for Nipah Virus InfectionU54AI057159 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WHELAN, SEAN PJ · 2003 to 2013
$113.7M
HARVARD CLINICAL AND TRANSLATIONAL SCIENCE CENTER (UL1)UL1RR025758 · NCRR · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2008 to 2011
$91.4M
Pilot & Feasibility ProgramP30DK043351 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Ramnik J Xavier · 1991 to 2026
$35.3M
Genomic Analysis of Network Perturbations in Human DiseaseP50HG004233 · NHGRI · DANA-FARBER CANCER INST · PI VIDAL, MARC · 2007 to 2017
$31.6M
Epstein-Barr Virus Nuclear Proteins in B Cell Growth TransformationR01CA047006 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ZHAO, BO · 2002 to 2021
$12.1M
Epstein-Barr Virus LMP-1 Mediated OncongenicityR01CA085180 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI KIEFF, ELLIOTT D · 2000 to 2016
$10.6M
VIRUS-HOST INTERACTIONS IN CANCERT32CA009031 · NCI · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI KIEFF, ELLIOTT D · 1985 to 2009
$2.4M
Genomic Approaches to Host-Pathogen InteractionsR01AI062773 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI XAVIER, RAMNIK J · 2006 to 2009
$1.4M
Genetic and Proteomic Analysis of Epstein-Barr Virus LMP1 Activation of NF-kBK08CA140780 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI GEWURZ, BENJAMIN ELISON · 2010 to 2014
$900k
NCI NIH HHS 5T32CA009031NCI NIH HHS K08 CA140780NCI NIH HHS K08CA140780NCI NIH HHS R01 CA047006NCI NIH HHS R01 CA085180NCI NIH HHS R01CA085180NCI NIH HHS R01CA47006NCI NIH HHS T32 CA009031NCRR NIH HHS UL1 RR025758NCRR NIH HHS UL1RR025758NHGRI NIH HHS P50 HG004233NIAID NIH HHS R01 AI062773NIAID NIH HHS R01AI062773NIAID NIH HHS U54 AI057159NIAID NIH HHS U54AI057159PHS HHS HGS5P50HG004233PHS HHS R01043351PHS HHS R0183756
6 · The paper itself

Abstract

Although canonical NFκB is frequently critical for cell proliferation, survival, or differentiation, NFκB hyperactivation can cause malignant, inflammatory, or autoimmune disorders. Despite intensive study, mammalian NFκB pathway loss-of-function RNAi analyses have been limited to specific protein classes. We therefore undertook a human genome-wide siRNA screen for novel NFκB activation pathway components. Using an Epstein Barr virus latent membrane protein (LMP1) mutant, the transcriptional effects of which are canonical NFκB-dependent, we identified 155 proteins significantly and substantially important for NFκB activation in HEK293 cells. These proteins included many kinases, phosphatases, ubiquitin ligases, and deubiquinating enzymes not previously known to be important for NFκB activation. Relevance to other canonical NFκB pathways was extended by finding that 118 of the 155 LMP1 NF-κB activation pathway components were similarly important for IL-1β-, and 79 for TNFα-mediated NFκB activation in the same cells. MAP3K8, PIM3, and six other enzymes were uniquely relevant to LMP1-mediated NFκB activation. Most novel pathway components functioned upstream of IκB kinase complex (IKK) activation. Robust siRNA knockdown effects were confirmed for all mRNAs or proteins tested. Although multiple ZC3H-family proteins negatively regulate NFκB, ZC3H13 and ZC3H18 were activation pathway components. ZC3H13 was critical for LMP1, TNFα, and IL-1β NFκB-dependent transcription, but not for IKK activation, whereas ZC3H18 was critical for IKK activation. Down-modulators of LMP1 mediated NFκB activation were also identified. These experiments identify multiple targets to inhibit or stimulate LMP1-, IL-1β-, or TNFα-mediated canonical NFκB activation.

Indexed as

Genome, HumanRNA, Small InterferingCell LineHumansInterleukin-1betaNF-kappa BTumor Necrosis Factor-alphaInterleukin-1betaNF-kappa BRNA, Small InterferingTumor Necrosis Factor-alpha

Identifiers

PMID22308454
PMCPMC3289371
OpenAlexW2110107948

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.